261 related articles for article (PubMed ID: 12636153)
21. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
22. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
Tang F; Ouyang H; Yang JZ; Borchardt RT
J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
[TBL] [Abstract][Full Text] [Related]
23. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
24. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
25. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
Batrakova EV; Li S; Miller DW; Kabanov AV
Pharm Res; 1999 Sep; 16(9):1366-72. PubMed ID: 10496651
[TBL] [Abstract][Full Text] [Related]
26. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
27. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
Zhang S; Morris ME
Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
[TBL] [Abstract][Full Text] [Related]
28. Chrysosplenetin inhibits artemisinin efflux in P-gp-over-expressing Caco-2 cells and reverses P-gp/MDR1 mRNA up-regulated expression induced by artemisinin in mouse small intestine.
Ma L; Wei S; Yang B; Ma W; Wu X; Ji H; Sui H; Chen J
Pharm Biol; 2017 Dec; 55(1):374-380. PubMed ID: 27931149
[TBL] [Abstract][Full Text] [Related]
29. Influence of passive permeability on apparent P-glycoprotein kinetics.
Lentz KA; Polli JW; Wring SA; Humphreys JE; Polli JE
Pharm Res; 2000 Dec; 17(12):1456-60. PubMed ID: 11303953
[TBL] [Abstract][Full Text] [Related]
30. Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells.
Takara K; Tsujimoto M; Ohnishi N; Yokoyama T
Biochem Biophys Res Commun; 2002 Mar; 292(1):190-4. PubMed ID: 11890691
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers.
Lowes S; Cavet ME; Simmons NL
Eur J Pharmacol; 2003 Jan; 458(1-2):49-56. PubMed ID: 12498906
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
33. Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.
Kigen G; Edwards G
BMC Pharmacol Toxicol; 2017 May; 18(1):20. PubMed ID: 28468637
[TBL] [Abstract][Full Text] [Related]
34. [Effect of Shaoyao Gancao Tang on function and expression of P-glycoprotein in Caco-2 cells].
Wang Y; Zhao J; Zhao Y; Li C; Yi Y; Liang A; Odd GN
Zhongguo Zhong Yao Za Zhi; 2012 Apr; 37(7):991-6. PubMed ID: 22792804
[TBL] [Abstract][Full Text] [Related]
35. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity.
Taipalensuu J; Tavelin S; Lazorova L; Svensson AC; Artursson P
Eur J Pharm Sci; 2004 Jan; 21(1):69-75. PubMed ID: 14706813
[TBL] [Abstract][Full Text] [Related]
36. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.
Hosoya KI; Kim KJ; Lee VH
Pharm Res; 1996 Jun; 13(6):885-90. PubMed ID: 8792427
[TBL] [Abstract][Full Text] [Related]
40. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
